Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.69 |
| ▸ | MAPK8 | P45983 | 11/20 | 0.61 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1680689 | 0.85 | PTK2 (0.73) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL13270043 | 0.83 | PTK2 (0.71) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL11946878 | 0.83 | PTK2 (0.71) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL5092793 | 0.81 | PTK2 (1.00) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL4357584 | 0.80 | PTPN2 (0.74) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL24488916 | 0.79 | PTK2 (0.70) | PTK2MAPK8MAPK10ALDH1A1MAPT | |
| SCHEMBL7056886 | 0.79 | PTK2 (0.70) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL20355791 | 0.79 | PTK2 (0.65) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL5478399 | 0.77 | PTK2 (0.63) | PTK2MAPK8MAPK10HTTALDH1A1 | |
| SCHEMBL19494280 | 0.77 | PTK2 (0.68) | PTK2MAPK8MAPK10HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | SPIRAL THERAPEUTICS INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | SPIRAL THERAPEUTICS INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2021087408-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | OTONOMY, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | OTC, SLC26A4, OAT | PTK2 4754/4885MAPK8 4415/4885MAPK10 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.